Compass Capital Management Inc. Sells 52,578 Shares of Zoetis Inc. $ZTS

Compass Capital Management Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 84.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,004 shares of the company’s stock after selling 52,578 shares during the period. Compass Capital Management Inc.’s holdings in Zoetis were worth $1,183,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Prosperity Bancshares Inc purchased a new position in Zoetis in the 4th quarter worth about $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the 1st quarter valued at about $28,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the 4th quarter valued at about $30,000. Root Financial Partners LLC boosted its position in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the period. Finally, Elyxium Wealth LLC bought a new position in Zoetis in the 4th quarter worth about $32,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 1.8%

Shares of NYSE ZTS opened at $77.37 on Friday. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48. The business has a fifty day moving average price of $77.05 and a 200 day moving average price of $102.49. The stock has a market capitalization of $32.44 billion, a P/E ratio of 12.83, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZTS. Citigroup decreased their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Barclays dropped their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. HSBC reduced their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average target price of $118.33.

Insider Buying and Selling

In other news, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock worth $886,384 in the last 90 days. 0.22% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.